Variable | Group | Estimate | Standard error | 95% Confidence limits | P value ANOVA/RMANOVA | P value Mann–Whitney U | |
---|---|---|---|---|---|---|---|
Lower | Upper | ||||||
Primary endpoint | |||||||
Modified GCPS score (without B) | Robenacoxib | 1.65 | 0.12 | 1.42 | 1.90 | 0.12 | 0.29 |
Meloxicam | 1.97 | 0.18 | 1.63 | 2.35 | |||
Unmodified GCPS score (with B) | Robenacoxib | 2.35 | 0.17 | 2.03 | 2.71 | 0.13 | 0.72 |
Meloxicam | 2.79 | 0.26 | 2.31 | 3.34 | |||
Secondary endpoints | |||||||
Pain at rest | Robenacoxib | 2.62 | 0.31 | 2.06 | 3.28 | 0.20 | 0.54 |
Meloxicam | 3.30 | 0.49 | 2.43 | 4.39 | |||
Pain at palpation/manipulation | Robenacoxib | 4.34 | 0.53 | 3.39 | 5.50 | 0.28 | 0.71 |
Meloxicam | 5.29 | 0.84 | 3.82 | 7.19 | |||
Global efficacy score | Robenacoxib | 0.45 | 0.06 | 0.33 | 0.58 | 0.28 | 0.22 |
Meloxicam | 0.56 | 0.09 | 0.39 | 0.76 | |||
Global inflammation score | Robenacoxib | 1.11 | 0.25 | 0.66 | 1.67 | 0.12 | 0.59 |
Meloxicam | 1.76 | 0.42 | 1.04 | 2.74 | |||
Owner assessment: demeanor | Robenacoxib | 0.10 | 0.02 | 0.07 | 0.13 | 0.96 | 0.62 |
Meloxicam | 0.10 | 0.02 | 0.06 | 0.14 | |||
Owner assessment: mobility | Robenacoxib | 0.10 | 0.03 | 0.05 | 0.16 | 0.17 | 0.098 |
Meloxicam | 0.05 | 0.03 | -0.01 | 0.12 |